יחס שווי שוק לשווי בספרים Entero Therapeutics Inc. (ENTO)

This chart of the market capitalization to net asset ratio visualizes the potential of Entero Therapeutics, Inc. (ENTO) to commercialize innovative molecules for the treatment of celiac disease. Growth prospects rely on demand from patients with gluten intolerance and tropical sprue. The value of 0.33 shows the latest metric value, while the absence of revenue makes the business dependent on external grants and investments.

The market evaluates the potential of Entero Therapeutics, Inc. (ENTO) through the lens of future successes in celiac disease therapy. The indicator is calculated as the ratio of market capitalization to net asset value, measuring the premium for intellectual capital. By analyzing this chart of the multiple between market value and the balance sheet, an investor can see the expectations for the monetization of enzyme developments. A high coefficient confirms the company's status as a high-tech biopharmaceutical asset.